6 results match your criteria: "Oregon Health and Science University Hospital and Clinics[Affiliation]"
Enteral tube administration of extemporaneously compounded suspensions of venetoclax according to an institutional medication use process.
J Oncol Pharm Pract
November 2024
Oregon Health and Science University Hospital and Clinics, Portland, OR, USA.
Introduction: Venetoclax is a potent oral oncology drug (OOD) frequently used to treat hematologic cancers due to its convenience and high efficacy. However, some patients cannot tolerate solid oral formulations, requiring a reformulated version of venetoclax for effective administration. Currently, there is limited information in the literature regarding the extemporaneous compounding of venetoclax.
View Article and Find Full Text PDFReply to Williams et al.
Open Forum Infect Dis
March 2024
Department of Medicine, UC Davis Health, Sacramento, California, USA.
Real-world Use of Mold-Active Triazole Prophylaxis in the Prevention of Invasive Fungal Diseases: Results From a Subgroup Analysis of a Multicenter National Registry.
Open Forum Infect Dis
September 2023
UC Davis Health, Sacramento, California, USA.
Article Synopsis
- Antifungal prophylaxis using mold-active triazoles (MATs) is effective in preventing invasive fungal diseases (IFDs) in high-risk, immunocompromised patients, as shown in a study with over 1,177 participants.
- The study found that breakthrough IFDs occurred in only 7.1% of patients, with different MATs showing varying percentages and specific pathogens identified.
- Adverse drug reactions (ADRs) were reported in 14.1% of patients, but discontinuation of MATs due to these reactions was relatively low at 11.1%, supporting their use in at-risk populations.
Managing the Mental Distress of the Hematopoietic Stem Cell Transplant (HSCT) Patient: a Focus on Delirium.
Curr Hematol Malig Rep
April 2018
Pharmacy Services, Oregon Health and Science University Hospital and Clinics, CR 9-4, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA.
Purpose Of Review: To highlight the breadth and types of mental distress experienced by hematopoietic stem cell transplant (HSCT) patients and highlight the need for better prevention and management of delirium.
Recent Findings: Recent publications highlight additional risks factors which predict for mental distress during the HSCT process. Despite new medications and additional psychological reports, there is little progress in non-pharmacologic or medication therapy in the prevention and treatment of delirium.
Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy.
Cancer Manag Res
September 2014
Oregon Health and Science University Hospital and Clinics, Portland, OR, USA.
Article Synopsis
- Chemotherapy can make cancer patients feel sick, and it's important to help prevent that nausea and vomiting (CINV).
- There are guidelines to help doctors treat nausea for one-day chemotherapy, but not many for treatments that last multiple days.
- Palonosetron is a medication that can help prevent CINV, especially for patients on multiple-day chemotherapy, and it worked well for two patients in a recent report.